Form 8-K Sage Therapeutics, Inc. For: Nov 09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Chardan Capital Markets Upgrades Sage Therapeutics (SAGE) to Buy
November 10, 2017 8:16 AM ESTChardan Capital Markets upgraded Sage Therapeutics (NASDAQ: SAGE) from Neutral to Buy with a price target of $140.00 following phase III Hummingbird data for brexanolone in PPD.
Analyst Gbola Amusa see a read-across from brexanolone in PPD to other vast-market indications, like MDD, Sage... More
Sage Therapeutics (SAGE) PT Raised to $135 at Cowen
November 9, 2017 3:20 PM ESTCowen raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $135.00 (from $90.00) while maintaining a Outperform rating following positive top-line data from the Ph3 HUMMINGBIRD trials of brexanolone in moderate and severe PPD.
Analyst Ritu Baral is optimistic that... More
Sage Therapeutics (SAGE) PT Raised to $105 at Stifel
November 9, 2017 12:43 PM ESTStifel raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $105.00 (from $91.00) while maintaining a Buy rating after the company reported positive top-line data from P3 Hummingbird trials with brexanolone (i.v. formulation) in postpartum depression (PPD).
Analyst Adam Walsh this... More
